Literature DB >> 19797329

Abnormal myocardial insulin signalling in type 2 diabetes and left-ventricular dysfunction.

Stuart A Cook1, Anabel Varela-Carver, Marco Mongillo, Christina Kleinert, Muhammad T Khan, Lucia Leccisotti, Nicola Strickland, Takashi Matsui, Saumya Das, Anthony Rosenzweig, Prakash Punjabi, Paolo G Camici.   

Abstract

AIMS: Whole body and myocardial insulin resistance are features of non-insulin-dependent diabetes mellitus (NIDDM) and left-ventricular dysfunction (LVD). We determined whether abnormalities of insulin receptor substrate-1 (IRS1), IRS1-associated PI3K (IRS1-PI3K), and glucose transporter 4 (GLUT4) contribute to tissue-specific insulin resistance. METHODS AND
RESULTS: We collected skeletal muscle (n = 27) and myocardial biopsies (n = 24) from control patients (n = 7), patients with NIDDM (n = 9) and patients with LVD (n = 8), who were characterized by euglycaemic-hyperinsulinaemic clamp and positron emission tomography. Comparative studies were carried out in three mouse models. We demonstrate an unrecognized reduction of IRS1 in skeletal muscle of LVD patients and an unexpected increase in cardiac IRS1-PI3K activity in NIDDM and LVD patients. In NIDDM, there was a concomitant reduction in sarcolemmal GLUT4, whereas in patients with LVD sarcolemmal GLUT4 was increased. We confirm activation of IRS1-PI3K and reduction in sarcolemmal GLUT4 in the insulin resistant ob/ob mouse heart where we also demonstrate perturbation of GLUT4 docking and fusion. A direct relationship between PI3K and GLUT4 was demonstrated in mice expressing activated PI3K in the heart and increased GLUT4 at the sarcolemma was confirmed in a mouse model of LVD.
CONCLUSION: Our data show that the mechanisms of myocardial insulin resistance are different between NIDDM and LVD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19797329      PMCID: PMC2800920          DOI: 10.1093/eurheartj/ehp396

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  37 in total

Review 1.  Glucose transporters and insulin action--implications for insulin resistance and diabetes mellitus.

Authors:  P R Shepherd; B B Kahn
Journal:  N Engl J Med       Date:  1999-07-22       Impact factor: 91.245

2.  Insulin receptor substrate-1 phosphorylation and phosphatidylinositol 3-kinase activity in skeletal muscle from NIDDM subjects after in vivo insulin stimulation.

Authors:  M Björnholm; Y Kawano; M Lehtihet; J R Zierath
Journal:  Diabetes       Date:  1997-03       Impact factor: 9.461

3.  Akt mediates the cross-talk between beta-adrenergic and insulin receptors in neonatal cardiomyocytes.

Authors:  Carmine Morisco; Gerolama Condorelli; Valentina Trimarco; Alessandro Bellis; Chiara Marrone; Gianluigi Condorelli; Junichi Sadoshima; Bruno Trimarco
Journal:  Circ Res       Date:  2004-12-09       Impact factor: 17.367

4.  Cardiac and skeletal muscle insulin resistance in patients with coronary heart disease. A study with positron emission tomography.

Authors:  G Paternostro; P G Camici; A A Lammerstma; N Marinho; R R Baliga; J S Kooner; G K Radda; E Ferrannini
Journal:  J Clin Invest       Date:  1996-11-01       Impact factor: 14.808

5.  Activation of c-Jun N-terminal kinases and p38-mitogen-activated protein kinases in human heart failure secondary to ischaemic heart disease.

Authors:  S A Cook; P H Sugden; A Clerk
Journal:  J Mol Cell Cardiol       Date:  1999-08       Impact factor: 5.000

Review 6.  Banting lecture 1988. Role of insulin resistance in human disease.

Authors:  G M Reaven
Journal:  Diabetes       Date:  1988-12       Impact factor: 9.461

7.  Efficacy of coronary angioplasty for the treatment of hibernating myocardium.

Authors:  F Fath-Ordoubadi; K J Beatt; N Spyrou; P G Camici
Journal:  Heart       Date:  1999-08       Impact factor: 5.994

8.  Insulin resistance and risk of congestive heart failure.

Authors:  Erik Ingelsson; Johan Sundström; Johan Arnlöv; Björn Zethelius; Lars Lind
Journal:  JAMA       Date:  2005-07-20       Impact factor: 56.272

9.  Relation among left ventricular mass, insulin resistance, and blood pressure in nonobese subjects.

Authors:  R A Phillips; L R Krakoff; A Dunaif; D T Finegood; R Gorlin; S Shimabukuro
Journal:  J Clin Endocrinol Metab       Date:  1998-12       Impact factor: 5.958

10.  Insulin receptor phosphorylation, insulin receptor substrate-1 phosphorylation, and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects.

Authors:  L J Goodyear; F Giorgino; L A Sherman; J Carey; R J Smith; G L Dohm
Journal:  J Clin Invest       Date:  1995-05       Impact factor: 14.808

View more
  68 in total

1.  Insulin suppresses ischemic preconditioning-mediated cardioprotection through Akt-dependent mechanisms.

Authors:  Tanner M Fullmer; Shaobo Pei; Yi Zhu; Crystal Sloan; Robert Manzanares; Brandon Henrie; Karla M Pires; James E Cox; E Dale Abel; Sihem Boudina
Journal:  J Mol Cell Cardiol       Date:  2013-08-30       Impact factor: 5.000

2.  Sex and type 2 diabetes: obesity-independent effects on left ventricular substrate metabolism and relaxation in humans.

Authors:  Linda R Peterson; Ibrahim M Saeed; Janet B McGill; Pilar Herrero; Kenneth B Schechtman; Ratnasiri Gunawardena; Carol L Recklein; Andrew R Coggan; Amanda J DeMoss; Carmen S Dence; Robert J Gropler
Journal:  Obesity (Silver Spring)       Date:  2011-08-04       Impact factor: 5.002

3.  Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese rats.

Authors:  Annayya R Aroor; James R Sowers; Shawn B Bender; Ravi Nistala; Mona Garro; Irina Mugerfeld; Melvin R Hayden; Megan S Johnson; Muhammad Salam; Adam Whaley-Connell; Vincent G Demarco
Journal:  Endocrinology       Date:  2013-05-07       Impact factor: 4.736

Review 4.  Mechanisms of subcellular remodeling in heart failure due to diabetes.

Authors:  Naranjan S Dhalla; Nobuakira Takeda; Delfin Rodriguez-Leyva; Vijayan Elimban
Journal:  Heart Fail Rev       Date:  2014-01       Impact factor: 4.214

5.  Myocardial oxygen consumption change predicts left ventricular relaxation improvement in obese humans after weight loss.

Authors:  C Huie Lin; Suraj Kurup; Pilar Herrero; Kenneth B Schechtman; J Christopher Eagon; Samuel Klein; Víctor G Dávila-Román; Richard I Stein; Gerald W Dorn; Robert J Gropler; Alan D Waggoner; Linda R Peterson
Journal:  Obesity (Silver Spring)       Date:  2011-07-07       Impact factor: 5.002

6.  Restoring redox balance enhances contractility in heart trabeculae from type 2 diabetic rats exposed to high glucose.

Authors:  Niraj M Bhatt; Miguel A Aon; Carlo G Tocchetti; Xiaoxu Shen; Swati Dey; Genaro Ramirez-Correa; Brian O'Rourke; Wei Dong Gao; Sonia Cortassa
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-12-05       Impact factor: 4.733

Review 7.  Insulin resistance protects the heart from fuel overload in dysregulated metabolic states.

Authors:  Heinrich Taegtmeyer; Christophe Beauloye; Romain Harmancey; Louis Hue
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-10-04       Impact factor: 4.733

8.  Glucose regulates the intrinsic inflammatory response of the heart to surgically induced hypothermic ischemic arrest and reperfusion.

Authors:  Ahmed S Bux; Merry L Lindsey; Hernan G Vasquez; Heinrich Taegtmeyer; Romain Harmancey
Journal:  Physiol Genomics       Date:  2016-12-09       Impact factor: 3.107

Review 9.  Heart Failure in Type 2 Diabetes Mellitus.

Authors:  Helena C Kenny; E Dale Abel
Journal:  Circ Res       Date:  2019-01-04       Impact factor: 17.367

10.  High-fat feeding-induced hyperinsulinemia increases cardiac glucose uptake and mitochondrial function despite peripheral insulin resistance.

Authors:  Anisha A Gupte; Laurie J Minze; Maricela Reyes; Yuelan Ren; Xukui Wang; Gerd Brunner; Mohamad Ghosn; Andrea M Cordero-Reyes; Karen Ding; Domenico Pratico; Joel Morrisett; Zheng-Zheng Shi; Dale J Hamilton; Christopher J Lyon; Willa A Hsueh
Journal:  Endocrinology       Date:  2013-05-24       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.